Omeros draws retail focus ahead of FDA decision on Narsoplimab

Omeros drew heavy retail attention ahead of an FDA decision due on December 26 on Narsoplimab, a treatment for post-stem cell transplant complications. Trading was halted pending news. Peer-reviewed data showed reduced mortality risk, while a European decision from the European Medicines Agency is expected in mid-2026.